Our previous study described the prognostic value of immune checkpoint inhibitors for AML patients by analyzing RNA-seq from the TCGA database and further validated results indicated that high expression of PD-1, PD-L1, and PD-L2 in the BM leukemia cells of AML patients correlated with poor outcomes (34). The gene discussed is PDCD1LG2; the disease is acute myeloid leukemia.